Story Stocks®

Updated: 07-Apr-26 10:59 ET
Healthcare Gets a Shot in the Arm as Medicare Advantage Rates Come in Stronger Than Expected (HUM)

Healthcare stocks are rallying after Centers for Medicare & Medicaid Services released its CY27 Medicare Advantage (MA) and Part D Rate Announcement, which came in meaningfully better than expected and eased concerns about ongoing margin pressure.

  • CMS projected a 2.48% average increase in MA payments for CY27, equating to over $13 bln in additional funding.
  • This compares to the preliminary estimate of just 0.09%, or ~$700 mln, representing a significant upside surprise.
  • The improved rates offer relief after a multi-year period of margin compression driven by policy changes and elevated utilization.
  • Some insurers had been scaling back MA exposure in weaker markets, but the updated rates may stabilize participation and pricing strategies.
  • The announcement also raises expectations that CMS may remain responsive to cost pressures heading into CY28, an election-year backdrop.
  • Health insurer stocks are responding positively, including UnitedHealth Group (UNH +8.3%), CVS Health (+6.2%), Humana (HUM +5.3%), Elevance Health (ELV +3%), and Centene (+1.6%).
  • UnitedHealth Group and Humana are leading the move due to their higher exposure to MA, with UnitedHealth holding ~29% share of MA enrollment.
  • Humana remains the most MA-exposed insurer, with 77.3% of its 2025 premium and services revenue tied to Individual and Group MA plans.

Briefing.com Analyst Insight:

This rate announcement provides a meaningful sentiment shift for the managed care group, which has been under pressure from a prolonged period of unfavorable rate updates and rising medical costs. The magnitude of the upside revision suggests CMS is becoming more attuned to insurer margin pressures, potentially reducing the risk of further market exits and benefit cuts. While one year does not reverse the structural challenges facing Medicare Advantage, it does improve near-term earnings visibility and supports the sharp rally in stocks with the highest MA leverage, particularly Humana. Investors will now look ahead to bid season and early CY28 signals to determine whether this marks a more durable turn in the rate environment.

Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.
Send
Chat Icon